Affibody is a Swedish biotech company focused on improving the treatment of a wide range of diseases through the generation of the next generation molecular imaging and drug candidates based on the company’s proprietary Affibody® technology.

The Company’s proprietary Affibody® molecules can be designed to bind specifically to a large number of target proteins that play an important role in the diagnosis or treatment of disease. These small and robust high affinity protein molecules are easily produced and are stable in a wide range of conditions.

Affibody® molecules are well suited for molecular imaging and as the same Affibody® molecule could be charged with a cytotoxic payload, it can potentially also be used for targeted therapy.

Affibody is also commercializing its unique albumin-binding technology designed to extend the half life of any biotherapeutic.

Affibody has developed biotechnological products that are commercialized by General Electric, Agilent and Finnzymes, and develops Affibody® molecules for further biotechnology applications in other commercial collaborations.

Affibody’s near term strategy for commercialization is through collaborations with leading Diagnostic and Pharmaceutical companies.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Bromma outside Stockholm, Sweden. Current shareholders in the Company include the investment companies HealthCap, Investor Growth Capital and SV Life Sciences.